BACKGROUND: This phase II study (S0027) evaluated the efficacy and tolerability of planned sequential single-agent chemotherapy with vinorelbine followed by docetaxel in patients with advanced non-small cell lung cancer (NSCLC) age 70 and older and/or a performance status (PS) of 2. METHODS: Patients with stage IIIB (pleural effusion) or stage IV NSCLC, age 70 and older with a PS of 0-1 or 2, any age, received three cycles of vinorelbine 25 mg/m days 1 and 8 every 21 days followed by three cycles of docetaxel 35 mg/m days 1, 8, and 15 every 28 days. RESULTS: A total of 125 patients entered the study; 117 patients were assessable for response, survival, and toxicity. Seventy-five patients were in stratum1 (age 70 and older, PS 0-1) and 42 patients in stratum 2 (PS 2, any age). Objective response was 19% (95% confidence interval [CI]: 11%-30%) and 11% (95% CI: 3%-25%) in strata 1 and 2, respectively. Median survival was 9.1 months (95% CI: 7.1-12.7) and 5.5 months (95% CI: 3.1-6.5) in strata 1 and 2, respectively. Survival at 12 months was 41% and 13% in strata 1 and 2, respectively. Grade 3/4 neutropenia was seen in 32% and 31% of patients in strata 1 and 2, respectively. Three deaths probably related to treatment were noted: one in stratum 1 and two in stratum 2. CONCLUSION: Sequential vinorelbine and docetaxel is a well-tolerated and effective regimen in comparison with reports of other treatments tested in patients with advanced NSCLC age 70 and older and/or with a PS of 2.
BACKGROUND: This phase II study (S0027) evaluated the efficacy and tolerability of planned sequential single-agent chemotherapy with vinorelbine followed by docetaxel in patients with advanced non-small cell lung cancer (NSCLC) age 70 and older and/or a performance status (PS) of 2. METHODS:Patients with stage IIIB (pleural effusion) or stage IV NSCLC, age 70 and older with a PS of 0-1 or 2, any age, received three cycles of vinorelbine 25 mg/m days 1 and 8 every 21 days followed by three cycles of docetaxel 35 mg/m days 1, 8, and 15 every 28 days. RESULTS: A total of 125 patients entered the study; 117 patients were assessable for response, survival, and toxicity. Seventy-five patients were in stratum1 (age 70 and older, PS 0-1) and 42 patients in stratum 2 (PS 2, any age). Objective response was 19% (95% confidence interval [CI]: 11%-30%) and 11% (95% CI: 3%-25%) in strata 1 and 2, respectively. Median survival was 9.1 months (95% CI: 7.1-12.7) and 5.5 months (95% CI: 3.1-6.5) in strata 1 and 2, respectively. Survival at 12 months was 41% and 13% in strata 1 and 2, respectively. Grade 3/4 neutropenia was seen in 32% and 31% of patients in strata 1 and 2, respectively. Three deaths probably related to treatment were noted: one in stratum 1 and two in stratum 2. CONCLUSION: Sequential vinorelbine and docetaxel is a well-tolerated and effective regimen in comparison with reports of other treatments tested in patients with advanced NSCLC age 70 and older and/or with a PS of 2.
Authors: Pamela J Atherton; Deborah W Watkins-Bruner; Carolyn Gotay; Carol M Moinpour; Daniel V Satele; Kathryn A Winter; Paul L Schaefer; Benjamin Movsas; Jeff A Sloan Journal: J Pain Symptom Manage Date: 2015-05-30 Impact factor: 3.612
Authors: Vega Iranzo; Rafael Sirera; Alfredo Carrato; Andrea Cabrera; Eloísa Jantus; Ricardo Guijarro; Elena Sanmartín; Ana Blasco; Mireia Gil; Lorenzo Gómez-Aldaraví; José Luis González-Larriba; Bertomeu Massuti; Amalia Velasco; Mariano Provencio; Rafael Rossell; Carlos Camps Journal: Clin Transl Oncol Date: 2011-06 Impact factor: 3.405
Authors: David Hui; Amy K Darke; Katherine A Guthrie; Ishwaria M Subbiah; Joseph M Unger; Dawn L Hershman; Robert S Krouse; Marie Bakitas; Mark A O'Rourke Journal: JCO Oncol Pract Date: 2021-10-04
Authors: Shirish M Gadgeel; Antoinette Wozniak; John C Ruckdeschel; Lance K Heilbrun; Raghu Venkatramanamoorthy; Ruth A Chaplen; Michael J Kraut; Gregory P Kalemkerian Journal: J Thorac Oncol Date: 2008-11 Impact factor: 15.609
Authors: Paul J Hesketh; Kari Chansky; Antoinette J Wozniak; Fred R Hirsch; Anna Spreafico; James Moon; Philip C Mack; Benjamin T Marchello; Wilbur A Franklin; John J Crowley; David R Gandara Journal: J Thorac Oncol Date: 2008-09 Impact factor: 15.609
Authors: Julia Mo; Amy K Darke; Katherine A Guthrie; Jeff A Sloan; Joseph M Unger; Dawn L Hershman; Mark O'Rourke; Marie Bakitas; Robert S Krouse Journal: JCO Oncol Pract Date: 2021-07-13
Authors: C Tibaldi; E Vasile; A Antonuzzo; R Di Marsico; A Fabbri; F Innocenti; G Tartarelli; D Amoroso; M Andreuccetti; M Lo Dico; A Falcone Journal: Br J Cancer Date: 2008-01-22 Impact factor: 7.640